138 related articles for article (PubMed ID: 27124967)
1. [Management of treatment in patients with neuroendocrine neoplasmas of digestive tract].
Kinová S; Kovácová M; Caprnda M; Koren M
Vnitr Lek; 2015 Dec; 61(12 Suppl 5):5S12-20. PubMed ID: 27124967
[TBL] [Abstract][Full Text] [Related]
2. [Management of treatment in patients with neuroendocrine neoplasmas of digestive tract].
Kiňová S; Kováčová M; Čaprnda M; Koreň M
Vnitr Lek; 2015; 61 Suppl 5():12-20. PubMed ID: 26800468
[TBL] [Abstract][Full Text] [Related]
3. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
5. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
7. Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report.
Søndenaa K; Sen J; Heinle F; Fjetland L; Gudlaugsson E; Syversen U
World J Surg; 2004 Sep; 28(9):890-5. PubMed ID: 15593463
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.
Khasraw M; Ananda S; Michael M
Expert Rev Anticancer Ther; 2016; 16(4):391-401. PubMed ID: 26808925
[TBL] [Abstract][Full Text] [Related]
9. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
10. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
Marotta V; Zatelli MC; Sciammarella C; Ambrosio MR; Bondanelli M; Colao A; Faggiano A
Endocr Relat Cancer; 2018 Jan; 25(1):R11-R29. PubMed ID: 29066503
[TBL] [Abstract][Full Text] [Related]
12. Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.
Khan TM; Garg M; Warner RR; Uhr JH; Divino CM
Pancreas; 2016 Aug; 45(7):1032-5. PubMed ID: 26684860
[TBL] [Abstract][Full Text] [Related]
13. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
14. The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition.
Pobłocki J; Jasińska A; Syrenicz A; Andrysiak-Mamos E; Szczuko M
Nutrients; 2020 May; 12(5):. PubMed ID: 32429294
[TBL] [Abstract][Full Text] [Related]
15. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
16. A jejunal stromal tumour in a patient with metastatic neuroendocrine cancer of unknown origin; a rare coexistence, diagnostic and therapeutic challenge.
El Ali Z; Iwanik K; Sowiński J; Swora E; Grzymislawski M
Endokrynol Pol; 2009; 60(3):216-20. PubMed ID: 19569023
[TBL] [Abstract][Full Text] [Related]
17. Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report.
Kos-Kudła B; Zemczak A; Foltyn W; Marek B; Strzelczyk J; Telega A; Zajecki W; Legaszewski T; Jurecka-Lubieniecka B
Endokrynol Pol; 2007; 58(2):123-9. PubMed ID: 17578828
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin As a Biochemical Marker of Neuroendocrine Tumors.
Lyubimova NV; Churikova TK; Kushlinskii NE
Bull Exp Biol Med; 2016 Mar; 160(5):702-4. PubMed ID: 27021085
[TBL] [Abstract][Full Text] [Related]
19. [Chromogranin A and neuroendocrine tumors].
Díaz Pérez JÁ; Currás Freixes M
Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and treatment options of neuroendocrine tumours].
Uhlyarik A; Pápai Z
Orv Hetil; 2013 Sep; 154(39):1549-55. PubMed ID: 24058100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
